Nektar Therapeutics (NKTR)
NASDAQ: NKTR · Real-Time Price · USD
0.6400
+0.0332 (5.47%)
Apr 17, 2025, 4:00 PM EDT - Market closed
Nektar Therapeutics Employees
Nektar Therapeutics had 61 employees as of December 31, 2024. The number of employees decreased by 76 or -55.47% compared to the previous year.
Employees
61
Change (1Y)
-76
Growth (1Y)
-55.47%
Revenue / Employee
$1,613,557
Profits / Employee
-$1,950,180
Market Cap
118.44M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novartis AG | 75,883 |
NKTR News
- 4 weeks ago - Nektar Therapeutics to Participate in the H.C. Wainwright 3rd Annual Autoimmune & Inflammatory Disease Virtual Conference - PRNewsWire
- 5 weeks ago - Nektar Therapeutics (NKTR) Q4 2024 Earnings Call Transcript - Seeking Alpha
- 5 weeks ago - Nektar Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results - PRNewsWire
- 6 weeks ago - Nektar to Announce Financial Results for the Fourth Quarter and Year-Ended 2024 on Wednesday, March 12, 2025, After Close of U.S.-Based Financial Markets - PRNewsWire
- 7 weeks ago - Nektar Therapeutics Announces Completion of Target Enrollment in REZOLVE-AA Phase 2b Clinical Trial of Rezpegaldesleukin in Patients with Severe-to-Very Severe Alopecia Areata - PRNewsWire
- 7 weeks ago - Nektar Announces Clinical Trial Agreement to Evaluate Rezpegaldesleukin in Patients with New Onset Type 1 Diabetes Mellitus - PRNewsWire
- 7 weeks ago - Nektar Therapeutics to Host Virtual Investor & Analyst Event with Type 1 Diabetes Experts on February 24th - PRNewsWire
- 2 months ago - Nektar Therapeutics Receives Fast Track Designation for Rezpegaldesleukin for the Treatment of Moderate-to-Severe Atopic Dermatitis - PRNewsWire